Wegovy is a glucagon-like peptide-1 (GLP-1) receptor agonist indicated as an adjunct to a reduced calorie diet and increased physical activity for chronic weight management (weight loss and weight maintenance) in adult patients with an initial body mass index (BMI) of 30 kg/m 2 or greater (obesity) or 27 kg/m 2 or greater (excess weight) in the presence of at least one weight related comorbid condition (e.g., hypertension, type 2 diabetes mellitus, or dyslipidemia)
Enhanced with Bioflavonoids The addition of Quercetin, Hesperidin, and Citrus Bioflavonoids helps protect Vitamin C from oxidation and boosts its antioxidant activity, supporting brighterlooking skin and overall skin health
Furthermore, in a study, Lactobacillus rhamnoses were encapsulated in a hydrogel that contains thiolated hyaluronic acid to treat Salmonella-induced enteritis
Treatment with the transcription inhibitor actinomycin D blocks GLP-1 stimulation of GLUT1 and hexokinase1 expression in these cells without affecting GLP-1 induction of insulin expression [464]
Recent approvals have expanded its use for patients with chronic kidney disease, helping to slow kidney function decline and reduce the risk of kidney failure
The agency has seized thousands of units of counterfeit Ozempic and is working with Novo Nordisk to investigate and remove suspected counterfeit products from the US supply chain (FDA 2024)